Dexcom Announces Leadership Transition as CEO Kevin Sayer Steps Down

Dexcom, a leading provider of continuous glucose monitoring (CGM) systems, has announced a significant leadership change. Kevin Sayer, who has served as CEO for a decade, will step down from his role, with current Chief Operating Officer Jake Leach set to take the helm.

Leadership Transition and Company Growth

Kevin Sayer, who became CEO in January 2015, will pass the torch to Jake Leach on January 1, 2026. Under Sayer's leadership, Dexcom has experienced remarkable growth, with revenues increasing tenfold from $402 million in 2015 to $4.03 billion in 2024. This growth has been attributed to expanded Medicare coverage for people with diabetes and the company's move into pharmacies, including the recent launch of an over-the-counter wearable tracker.

Jake Leach, a 21-year veteran of Dexcom, has served in various leadership roles, including Chief Technology Officer and Chief Operating Officer. In May 2025, he was promoted to the position of President and COO, preparing him for the upcoming transition to CEO.

Sayer expressed confidence in Leach's ability to lead the company, stating, "There is nobody that I trust more than Jake to lead the company into the future." After the transition, Sayer will remain involved with Dexcom as Executive Chairman of the Board.

Product Developments and Financial Performance

Dexcom is poised to roll out its updated G7 sensor with an extended 15-day lifespan, following FDA approval in April 2025. This launch, scheduled for fall 2025, represents a significant advancement in the company's product portfolio.

The company's financial performance remains strong, with Q2 2025 global revenue reaching $1.16 billion, a 15% increase from the previous year. Net income for the quarter stood at $179.8 million. In light of these results, Dexcom has raised its full-year 2025 guidance, projecting revenue between $4.600 billion and $4.625 billion, maintaining a 14% to 15% growth trajectory.

Competitive Landscape and Future Outlook

As Dexcom prepares for this leadership transition, the company faces growing competition in the CGM sector. Rivals such as Abbott are expanding integrations with automated insulin delivery systems, and the FDA has authorized longer-lasting implantable sensors. In response to market demands, both Dexcom and Abbott launched the first over-the-counter glucose sensors in 2024.

Leach remains optimistic about Dexcom's future, stating, "When I look at the future potential for Dexcom, I can honestly say I believe this company is just getting started. We have an incredible team, and I'm excited to lead the next phase of our journey to both expand access to our technology and to innovate across our portfolio of products to drive better health outcomes for our customers."